The company is actively working to reduce excess inventory in North America, and it is focusing on selling products at full price through its own channels. This could affect its overall revenue growth.
CrispIdea equity reports provide valuable insights to investors who may be individuals and organizations involved in the world of finance and investment like private equity houses, broking firms, hedge funds, investment advisory firms, mutual funds, banks and corporations. This research report is useful for M&A, business & investment analysis to all students and researchers also.
CrispIdea equity reports include basic financials, strategic analysis, competitive landscape assessments, stock performance, stock analysis and future growth potential evaluation. CrispIdea utilizes a proprietary blend of fundamental and technical analysis, offering a unique perspective. Reports present clear investment recommendations (“BUY,” “HOLD,” or “SELL”).
Our established reputation and track record advocates that our research carries weight within the investment community. Do connect with us, if you are looking for customized research, equity valuation, recommendation, analysis and market recommendation for any specific company, sector and industry.
adidas AG, together with its subsidiaries, designs, develops, produces, and markets athletic and sports lifestyle products in Europe, the Middle East, Africa, North America, Greater China, the Asia-Pacific, and Latin America.
In Q3FY23, ADS’s revenue declined by 6% to €5.999bn from €6.408bn in Q3FY22. Currency-neutral revenues increased 1% in Q3FY23. The diluted EPS declined by 24% to €0.45 from €1.91 in the same period.
Adidas stock gave returns of -3.9% and 23.1% in the period of three months and one year. The stock price has decreased from €193.64 as of Dec 04, 2023 to €187 as of Mar 01, 2024. The stock gave returns of -35.4% and CAGR of -13.6% over a period of three years. The stock had a 200-Day Moving Average of €175.95 and a 50-Day Moving Average of €177.65.
Highlights
Valuation
– Enterprise Value
– CrispIdea Forecast
– Economic Value Added Analysis
– P/E Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum
Actual & Historical Performance
– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– Key Metrics
– M&A Deals
Peer Performance
– Summary
– Profitability
– Growth
– Price Performance
Ownership
Stock Price Performance
Crispidea Coverage
$280.00
Scan this QR code using your UPI app.
Amount: ₹499
malay.ia@validhdfc
After payment, email your transaction ID or payment confirmation to [email protected] , along with your name and email address. We'll verify your payment and email the report.
STMicroelectronics N.V. Q3FY26 - ST is expanding its supply of optical transceivers and power chips to cloud datacenter builders.
$240.00
Meta Platforms, Inc (Q3FY26) - Meta delivered Q3FY26 revenue of $64.6bn, up 26% YoY, with ad revenue of $63.1bn also up 26% on a constant currency basis.
$240.00
General Dynamics Corporation Q3FY26 - During 9MFY26, the aerospace and defense sector delivered high single digit top line growth YoY, supported by steady European defense rearmament and solid demand for commercial airframes.
$240.00
Twist Bioscience Corporation (Q3FY26) - Twist’s revenue expansion is primarily driven by volume gains across its Next-Generation Sequencing (NGS) target enrichment panels and synthetic biology tools.
$224.00
Capital Deployment - 2026 highlights key themes including the move away from physical assets and bank deposits towards equity and alternative investments, the democratization of high-yield asset classes through technology, and the surge in retail participation driven by mobile-first platforms and open banking infrastructure.
$225.00
A new Samvat brings fresh opportunities, and new questions for investors. As market conditions shift and valuations reset, which stocks deserve a place on your watchlist? Discover 10 research-backed stock ideas for Samvat 2083, selected through CrispIdea’s multi-factor scoring model and analysed for earnings potential, business fundamentals and valuation.
₹499.00
The Consumerization of Healthcare - 2026: Gen Z and younger Millennials are fundamentally rewriting the rules of healthcare. Instead of relying on a primary care physician as the first point of contact, their healthcare journey now begins with a TikTok video, a Reddit thread, or a conversation with an AI chatbot.
$850.00
The Magnificent Seven: H1 2026 Performance - The consolidated YTD 2026 performance highlights a positive yet uneven trajectory across the mega-cap technology universe, with returns concentrated among a few leading names.
$125.00